机构：[1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[2]Med-X Center for Informatics, Sichuan University, Chengdu, 610041, China[3]Laboratory of Human Diseases & Immunotherapies, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[4]Institute of Immunology & Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院
Purpose: To evaluate the cost-effectiveness of atezolizumab plus chemotherapy as first-line treatment for metastatic urothelial cancer (mUC). Materials & methods: A Markov model was established for the analysis. Parametric survival models were used to fit to progression-free survival and overall survival data in the IMvigor130 study. A series of one-way and probabilistic sensitivity analyses were performed to test the robustness of the model. Results: The incremental cost-effectiveness ratios for atezolizumab plus chemotherapy versus chemotherapy alone were US$475,633.17 and $207,488.17 per quality-adjusted life year in the USA and China, respectively. Utility for the progression-free survival and progressive disease states, the cost of atezolizumab had the most significant impact on the incremental cost-effectiveness ratio. Conclusion: Atezolizumab plus chemotherapy is not a cost-effective treatment option as a first-line treatment for metastatic urothelial cancer.
基金：
This work was funded by the National Natural and Scientific Foundation of China (No. 81572988) and Science & Technology
Department of Sichuan Province Funding Project (2018SZ0117).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|4 区医学
小类|4 区卫生保健与服务
最新[2023]版：
大类|4 区医学
小类|4 区卫生保健与服务
第一作者：
第一作者机构：[1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China[2]Med-X Center for Informatics, Sichuan University, Chengdu, 610041, China[3]Laboratory of Human Diseases & Immunotherapies, West China Hospital, Sichuan University, Chengdu, 610041, China[4]Institute of Immunology & Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China
通讯作者：
通讯机构：[1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China[2]Med-X Center for Informatics, Sichuan University, Chengdu, 610041, China
推荐引用方式(GB/T 7714)：
Zhang Peng-Fei,Wen Feng,Wu Qiu-Ji,et al.Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis[J].Journal of comparative effectiveness research.2022,11(14):1021-1030.doi:10.2217/cer-2022-0064.
APA：
Zhang Peng-Fei,Wen Feng,Wu Qiu-Ji&Li Qiu.(2022).Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis.Journal of comparative effectiveness research,11,(14)
MLA：
Zhang Peng-Fei,et al."Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis".Journal of comparative effectiveness research 11..14(2022):1021-1030
